Skip to main content

Advertisement

Log in

Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Few studies have evaluated metabolic activity by 18F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC.

Methods

We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment 18F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. StomachSUVmax was defined as SUVmax in the stomach, while TotalSUVmax was defined as the highest SUVmax among all the target lesions.

Results

The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1 % of patients). A TotalSUVmax value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a TotalSUVmax value <11.5 than in those with a TotalSUVmax value ≥11.5 (P = 0.023); however, overall survival (OS) was not (P = 0.055). A StomachSUVmax value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a StomachSUVmax value <6.0 than in those with a StomachSUVmax value ≥6.0 (P = 0.001 and P = 0.006, respectively). Furthermore, those with a low TotalSUVmax and those with a low StomachSUVmax showed better chemotherapeutic responses (P = 0.016 and P = 0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower TotalSUVmax and those with lower StomachSUVmax showed longer median PFS (P = 0.027 and P = 0.005, respectively) and OS (P = 0.009 and P <0.001, respectively). Multivariate analysis demonstrated StomachSUVmax as an independent predictor of PFS (P = 0.002) and OS (P = 0.038).

Conclusion

Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, StomachSUVmax was the single, most robust factor predicting prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lee H, Yang H, Ahn Y. Gastric cancer in Korea. Gastric Cancer. 2002;5:177–82.

    Article  PubMed  Google Scholar 

  2. Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kühl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging. 2006;31:25–35.

    Article  PubMed  CAS  Google Scholar 

  3. Kim S, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33:148–55.

    Article  PubMed  Google Scholar 

  4. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192–6.

    Article  PubMed  Google Scholar 

  5. Chen J, Cheong J, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005;103:2383–90.

    Article  PubMed  Google Scholar 

  6. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690–99.

    PubMed  CAS  Google Scholar 

  7. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–51.

    Article  PubMed  Google Scholar 

  8. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–64.

    Article  PubMed  CAS  Google Scholar 

  9. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–44.

    PubMed  CAS  Google Scholar 

  10. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73:1151–57.

    PubMed  Google Scholar 

  11. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–300.

    Article  PubMed  CAS  Google Scholar 

  12. Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604–10.

    Article  PubMed  CAS  Google Scholar 

  13. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012–18.

    Article  PubMed  CAS  Google Scholar 

  14. Chung HW, Lee EJ, Cho Y, Yoon SY, So Y, Kim S, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.

    Article  PubMed  Google Scholar 

  15. Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol. 2010;8:86.

    Article  PubMed  Google Scholar 

  16. Hamilton SR, Aaltonen LA. World Health Organisation classification of tumours. Pathology and genetics of tumours of the digestive System. Lyon: IARC; 2000.

    Google Scholar 

  17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  PubMed  CAS  Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  19. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44.

    Article  PubMed  CAS  Google Scholar 

  20. Zheng Y, Cai T, Feng Z. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics. 2006;62:279–87.

    Article  PubMed  Google Scholar 

  21. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47:458–72.

    Article  PubMed  Google Scholar 

  22. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:468–82.

    Article  PubMed  Google Scholar 

  23. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–5.

    Article  PubMed  CAS  Google Scholar 

  24. Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res. 2009;15:2426–32.

    Article  PubMed  CAS  Google Scholar 

  25. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, et al. (18)F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011. doi:10.1002/cncr.26099.

  26. Park JC, Lee YC, Kim J, Kim YJ, Lee SK, Shin SK, et al. Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. Ann Surg Oncol. 2010;17:829–37.

    Article  PubMed  Google Scholar 

  27. Park JC, Lee YC, Kim J, Kim YJ, Lee SK, Hyung WJ, et al. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009;99:395–401.

    Article  PubMed  Google Scholar 

  28. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert J, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288–95.

    Article  PubMed  CAS  Google Scholar 

  29. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634–41.

    Article  PubMed  CAS  Google Scholar 

  30. Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005;128:2289–97.

    Article  PubMed  Google Scholar 

  31. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci A. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg. 2004;78:1017–23.

    Article  PubMed  Google Scholar 

  32. Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255–59.

    PubMed  Google Scholar 

  33. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.

    Article  PubMed  Google Scholar 

  34. Lee K, Lee S, Kim D, Kang WJ, Chung J, Im S, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res. 2006;12:4232–36.

    Article  PubMed  CAS  Google Scholar 

  35. Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol. 2009;4:875–79.

    Article  PubMed  Google Scholar 

  36. Na II, Byun BH, Kang HJ, Cheon GJ, Koh JS, Kim CH, et al. 18F-Fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res. 2008;14:2036–41.

    Article  PubMed  CAS  Google Scholar 

  37. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247–53.

    Article  PubMed  Google Scholar 

  38. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43:256–64.

    Article  PubMed  CAS  Google Scholar 

  39. Park J, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008;2:137–44.

    PubMed  Google Scholar 

  40. Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat. 2010;42:24–9.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong Chan Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, J.C., Lee, JH., Cheoi, K. et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 39, 1107–1116 (2012). https://doi.org/10.1007/s00259-012-2116-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-012-2116-x

Keywords

Navigation